Author

Brian G. Feagan 1

1 The University of

A CLUSTER-RANDOMISED CONTROLLED TRIAL OF AN ENHANCED TREATMENT ALGORITHM FOR THE MANAGEMENT OF CROHN’S DISEASE: REACT-2

Vipul Jairath, Reena Khanna, Leonard Guizzetti, Guangyong Zou, Joan Morris, Lisa Shackelton, Parambir Dulai, Humberto Aguilar, Oliver Brain, Matthew Brookes, Aminda De Silva, Michael S Epstein, Baroudi Fashir, John N. Gordon, William Harlan III, Ulf Helwig, Caroline Hwang, Pierre Laflamme, Rebecca Matro, Mark C. Mattar;;

A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF THE ORAL, GUT-RESTRICTED ALPHA4BETA7 INTEGRIN PEPTIDE ANTAGONIST PN-943 IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS FROM THE IDEAL STUDY

Scott Plevy, Bruce E. Sands, Julian Panés, Geert R. D'Haens, Vipul Jairath, Brian G. Feagan, Suneel Gupta, C. C. Hwang, Scott Lee, Alessandro Armuzzi, Walter Reinisch, Stefan Schreiber, William J. Sandborn

ALICAFORSEN ENEMA IN CHRONIC POUCHITIS: RESULTS OF A PHASE 3 RANDOMIZED, DOUBLE BLIND PLACEBO-CONTROLLED TRIAL

Nermeen Varawalla, James Lindsay, Brian Feagan, Gordon Moran

AN ADDITIONAL 12 WEEKS OF RISANKIZUMAB THERAPY INDUCES CLINICAL RESPONSE IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO FAILED TO ACHIEVE CLINICAL RESPONSE AFTER AN INITIAL INDUCTION PERIOD: 24-WEEK POOLED ANALYSIS OF TWO PHASE 3 STUDIES

Geert R. D'Haens, Brian Feagan, William J. Sandborn, Remo Panaccione, Julian Panés, Tadakazu Hisamatsu, Marc Ferrante, Ezequiel Neimark, Peter Bossuyt, Silvio Danese, Alexandra Song, Xiaomei Liao, Tian Feng, Rachel Duan, Sofie Berg, Jean-Frédéric Colombel, Kori Wallace

ASSESSMENT OF COMPOSITE ENDPOINTS COMPRISING SYMPTOMATIC, HISTOLOGIC, ENDOSCOPIC, AND MOLECULAR IMPROVEMENT IN A PHASE 1B STUDY OF GB004, A GUT-TARGETED, HYPOXIA-INDUCIBLE FACTOR (HIF)-1Α STABILIZER, IN MILD-TO-MODERATE ULCERATIVE COLITIS

Kartik Raghupathi, Robin Osterhout, Brian Feagan, William J. Sandborn, Courtney Van Biene, Allan Olson, Richard Aranda, Barrett G. Levesque, Silvio Danese

ASSESSMENT OF HISTOLOGICAL REMISSION IN PATIENTS TREATED WITH FILGOTINIB BY DIFFERENT SCORES AND CONCORDANCE WITH ENDOSCOPIC AND HEALTH-RELATED QUALITY OF LIFE OUTCOMES: POST HOC ANALYSIS FROM THE SELECTION STUDY

Fernando Magro, Laurent Peyrin-Biroulet, Gerhard Rogler, Alessandra Oortwijn, Haridarshan Patel, Angela de Haas, Eva Santermans, Haoyao Ruan, Louis Dron, Brian G. Feagan

ASSOCIATION OF HISTOLOGIC MEASUREMENT WITH ENDOSCOPIC OUTCOMES AFTER ONE YEAR OF TREATMENT WITH MIRIKIZUMAB IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE

Fernando Magro, Gert De Hertogh, Marijana Protic, Lai Shan Chan, Paul Pollack, Brian G. Feagan, Noam Harpaz, Rish Pai, Walter Reinisch

BENEFIT OF PROLONGED FILGOTINIB DOSING IN PATIENTS WITH ULCERATIVE COLITIS WHO DID NOT RESPOND TO INDUCTION THERAPY: DATA FROM THE SELECTION LONG-TERM EXTENSION STUDY

Severine Vermeire, Alessandra Oortwijn, Simon Hatch, Silvio Danese, Toshifumi Hibi, Brian Feagan, William J. Sandborn

BENEFITS OF HIGH VERSUS LOW DOSE UPADACITINIB AS MAINTENANCE TREATMENT IN ULCERATIVE COLITIS PATIENTS WHO WERE RESPONDERS TO 8-WEEK INDUCTION WITH UPADACITINIB: RESULTS FROM THE U-ACHIEVE PHASE 3 MAINTENANCE TRIAL

Brian G. Feagan

BENEFITS OF HIGH VERSUS LOW DOSE UPADACITINIB AS MAINTENANCE TREATMENT IN ULCERATIVE COLITIS PATIENTS WHO WERE RESPONDERS TO 8-WEEK INDUCTION WITH UPADACITINIB: RESULTS FROM THE U-ACHIEVE PHASE 3 MAINTENANCE TRIAL

Brian G. Feagan, Gareth Parkes, Pascal Juillerat, Krisztina Barbara Gecse, Xuan Yao, Wen Zhou, Huiwen Deng, Dapo Ilo, Yuri Sanchez Gonzalez, Peter D.R. Higgins

Item 1 - 10 / 37
1
2 3 4